Nestle gets peanut allergy treatment with $2 billion Aimmune buyout
Nestle (NESN.S) will pay $2 billion to buy the remaining stake in Aimmune Therapeutics Inc (AIMT.O), gaining full ownership of the first U.S.-approved peanut allergy treatment which has struggled with a slow launch due to the COVID-19 pandemic. Nestle said on Monday its offer for Aimmune values the California-based drugmaker, in which it already has […]
Continue Reading